Ryan D. Maynard
Independent DirectorMr. Ryan D. Maynard is Chief Financial Officer of Foghorn Therapeutics Inc. from February 23, 2026. Mr. Maynard served as Chief Financial Officer at Cara Therapeutics, Inc. since September 12, 2022 until 2025. Mr. Maynard had been Chief Financial Officer at PrivaPath Diagnostics Limited. Prior to joining Cara, Mr. Maynard served as the Chief Financial Officer of LetsGetChecked, a global healthcare solutions company, from October 2019 to March 2022 and served as its Treasurer. He served as the Chief Financial Officer of Paulus Holdings Ltd. Mr. Maynard served as Chief Financial Officer of Blade Therapeutics, Inc. since February 27, 2018 until June 2019. Mr. Maynard was Chief Financial Officer of Rigel Pharmaceuticals Inc. (“Rigel”) since 2001 until December 31, 2017. He joined Rigel in September 2001 as Corporate Controller and was appointed as an Assistant Secretary in October 2001. He served as Executive Director of Finance, Accounting and Purchasing of Rigel in October 2005. Mr. Maynard served as Corporate Controller and Director of Finance and Accounting for Personify, Inc., from November 1999 to April 2001. He served as Controller of General Magic, Inc. since July 1998 until October 1999 and from July 1994 to June 1998, he held various positions at Siliconix, Inc., served as Senior Finance Manager. He has been an Independent Director of Iovance Biotherapeutics, Inc. (Formerly, Lion Biotechnologies, Inc.) since February 16, 2015. He previously worked at Ernst & Young, LLP. Beginning January 2004, Mr. Maynard served as a Senior Director of Rigel. He is a Certified Public Accountant from AICPA. Mr. Maynard holds a B.S. degree in Commerce and Accounting from Santa Clara University.
Positions
- Company NameIovance Biotherapeutics, Inc.Stock CodeIOVAPositionIndependent DirectorColleagues
- FGFrederick G. VogtInterim CEO, President, General Counsel, Corporate Secretary & Director
- IDIain D. DukesIndependent Chairman of the Board
- CMCorleen M. RocheChief Financial Officer
- IPIgor P. BilinskyChief Operating Officer
- RKRaj K. PuriChief Regulatory Officer
- DGDaniel G. KirbyChief Commercial Officer
- MWMichael WeiserIndependent Director
- CYCassian YeeMember of Scientific Advisory Board
